These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Lebrin F; Srun S; Raymond K; Martin S; van den Brink S; Freitas C; Bréant C; Mathivet T; Larrivée B; Thomas JL; Arthur HM; Westermann CJ; Disch F; Mager JJ; Snijder RJ; Eichmann A; Mummery CL Nat Med; 2010 Apr; 16(4):420-8. PubMed ID: 20364125 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life. Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273 [TBL] [Abstract][Full Text] [Related]
5. Thalidomide for hereditary haemorrhagic telangiectasia. Franchini M; Lippi G Lancet Haematol; 2015 Nov; 2(11):e457-8. PubMed ID: 26686252 [No Abstract] [Full Text] [Related]
6. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Penaloza A; Vekemans MC; Lambert C; Hermans C Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956 [TBL] [Abstract][Full Text] [Related]
7. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. Harrison L; Kundra A; Jervis P J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Invernizzi R; Quaglia F; Klersy C; Pagella F; Ornati F; Chu F; Matti E; Spinozzi G; Plumitallo S; Grignani P; Olivieri C; Bastia R; Bellistri F; Danesino C; Benazzo M; Balduini CL Lancet Haematol; 2015 Nov; 2(11):e465-73. PubMed ID: 26686256 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide. Lacout A; Marcy PY; El Hajjam M; Lacombe P Med Hypotheses; 2013 May; 80(5):587-8. PubMed ID: 23452644 [TBL] [Abstract][Full Text] [Related]
11. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Parambil JG; Woodard TD; Koc ON Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965 [TBL] [Abstract][Full Text] [Related]
12. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Harrison DF Laryngoscope; 1982 Mar; 92(3):314-20. PubMed ID: 7040867 [No Abstract] [Full Text] [Related]
13. Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. Halderman AA; Ryan MW; Clark C; Sindwani R; Reh DD; Poetker DM; Invernizzi R; Marple BF Int Forum Allergy Rhinol; 2018 Jun; 8(6):713-728. PubMed ID: 29393992 [TBL] [Abstract][Full Text] [Related]
14. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Yaniv E; Preis M; Shevro J; Nageris B; Hadar T Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Sabbà C; Gallitelli M; Palasciano G N Engl J Med; 2001 Sep; 345(12):926. PubMed ID: 11565536 [No Abstract] [Full Text] [Related]
18. In reference to hereditary hemorrhagic telangiectasia/avastin. Bachmann-Harildstad G Laryngoscope; 2010 Oct; 120(10):2134. PubMed ID: 20824638 [No Abstract] [Full Text] [Related]